Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06121180 | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | PHASE2 | RECRUITING | 32 | — | — | Nov 4, 2024 | Oct 31, 2030 | Dec 4, 2025 | 4 | United States |
objective response rate as defined by Complete response (CR) plus partial response (PR) as assessed by RECIST criteria version 1.1.
| Arm | Type | Description |
|---|---|---|
| Cemiplimab + Ziv-Aflibercept | EXPERIMENTAL | One cycle consists of 3 weeks during which: Cemiplimab 350 mg administered IV every 3 weeks given with Ziv-Aflibercept 4 mg/kg administered IV every 2 weeks. |
| Name | Type | Description |
|---|---|---|
| ZIV-Aflibercept | DRUG | Ziv-Aflibercept is an investigational or experimental anti-cancer agent inactivates vascular endothelial growth factor (VEGF) from functioning and scientific experiments have shown that when VEGF is prevented from working, new blood vessels don't form in tumors and these tumors do not grow. In addition, VEGF has been shown to have a negative effect on the immune response and blocking it may help the immune response against cancer. |
| Cemiplimab | DRUG | Cemiplimab is a human monoclonal anti-PD-1 antibody that works by blocking the programmed death-1 (PD-1), a cell receptor on immune cells that is involved in preventing immune cells from destroying other cells. Blocking the receptor is expected to help immune cells attack cancer cells. |
Inclusion Criteria: * Provision of signed and dated informed consent form. * Male or female, aged \>/= 18 years old. * Life expectancy of greater than 3 months in the opinion of the investigator. * Must be willing and able to provide informed consent signed by study patient or legally acceptable re...